LivaNova (NASDAQ:LIVN) Director Brooke Story Sells 2,300 Shares

LivaNova PLC (NASDAQ:LIVN) Director Brooke Story sold 2,300 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. This trade represents a 23.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $80.70 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The stock has a market cap of $4.45 billion, a PE ratio of 23.88 and a beta of 0.87. The stock’s fifty day simple moving average is $80.63 and its two-hundred day simple moving average is $73.14. LivaNova PLC has a 1-year low of $48.82 and a 1-year high of $85.76.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.05 EPS. As a group, analysts forecast that LivaNova PLC will post 3.77 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in LivaNova by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after buying an additional 36,094 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after buying an additional 15,405 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio purchased a new stake in LivaNova in the 1st quarter worth about $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LIVN shares. Mizuho increased their price objective on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Needham & Company LLC boosted their price objective on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Finally, Zacks Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and an average price target of $84.12.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.